---
title: "Fangsheng Pharmaceutical: Clinical trial for Relugolix tablets approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261208730.md"
description: "According to the Zhitong Finance APP, Fangsheng Pharmaceutical announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as \"Fangsheng Jianmeng\"), has received the \"Drug Clinical Trial Approval Notification\" issued by the National Medical Products Administration, approving the clinical trial of this product for prostate cancer"
datetime: "2025-10-15T08:48:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261208730.md)
  - [en](https://longbridge.com/en/news/261208730.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261208730.md)
---

# Fangsheng Pharmaceutical: Clinical trial for Relugolix tablets approved

According to the Zhitong Finance APP, Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (referred to as "Fangsheng Jianmeng") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial of this product for prostate cancer

### Related Stocks

- [603998.CN](https://longbridge.com/en/quote/603998.CN.md)

## Related News & Research

- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)